Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
14,242
Stocks News & Analysis
stocks
Cheap e-commerce share continues sales momentum
stocks
Chart of the Week: Booming mined commodity prices see little value on offer
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,819.60 | 65.10 | -0.73% |
| CAC 40 | 8,207.89 | 34.78 | 0.43% |
| DAX 40 | 25,177.80 | 7.09 | -0.03% |
| Dow JONES (US) | 50,644.28 | 182.60 | 0.36% |
| FTSE 100 | 10,502.00 | 3.01 | -0.03% |
| HKSE | 25,002.29 | 325.94 | -1.29% |
| NASDAQ | 26,674.73 | 18.55 | 0.07% |
| Nikkei 225 | 64,693.12 | 306.29 | -0.47% |
| NZX 50 Index | 13,206.11 | 21.70 | -0.16% |
| S&P 500 | 7,520.36 | 1.24 | 0.02% |
| S&P/ASX 200 | 8,592.90 | 61.60 | -0.71% |
| SSE Composite Index | 4,097.64 | 3.91 | 0.10% |